NEORX CORPORATION

Company Information
Address 410 W HARRISON ST
SEATTLE, WA, 98119


Information

DUNS:

# of Employees: N/A


Ownership Information

Hubzone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. GEMCITABINE POTENTIATION OF PRETARGET RIT

    Amount: $108,679.00

    DESCRIPTION: Each year in the United States there are more than 20,000 deaths from pancreatic cancer. Gemcitabine is a cytarabine analogue that has been shown to be effective in prolo ...

    SBIRPhase I2001Department of Health and Human Services
  2. N/A

    Amount: $104,167.00

    N/A

    SBIRPhase II2000Department of Health and Human Services
  3. N/A

    Amount: $100,000.00

    N/A

    STTRPhase I2000Department of Health and Human Services
  4. N/A

    Amount: $0.00

    N/A

    SBIRPhase I2000Department of Health and Human Services
  5. ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212

    Amount: $753,164.00

    N/A

    SBIRPhase II1998Department of Health and Human Services
  6. COLD STORAGE OF PLATELETS

    Amount: $95,839.00

    N/A

    SBIRPhase I1997Department of Health and Human Services
  7. ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212

    Amount: $100,000.00

    N/A

    SBIRPhase I1997Department of Health and Human Services
  8. CONJUGATION OF SMALL RIBOSOMAL INHIBITORS TO ANTIBODIES

    Amount: $50,000.00

    NEORX CORPORATION PROPOSES A NEW SERIES OF SMALL-MOLECULAR WEIGHT NATURAL PRODUCTS THAT ARE SIMILAR TO HIGHER PLANT TOXINS IN THEIR MECHANISMS OF ACTION-INHIBITING PROTEIN SYNTHESIS AT THE LEVEL OF TH ...

    SBIRPhase I1987Department of Health and Human Services
  9. RADIOIODINATED CONJUGATES FOR THERAPY AND DIAGNOSIS

    Amount: $500,000.00

    THE PURPOSE OF THIS CONTRACT PROPOSAL IS TO DEVELOP NEW RADIOIODINE-LABELED CONJUGATES FOR MONOCLONAL ANTIBODIES THAT CAN BE USED IN DIAGNOSIS AND THERAPY OF CANCER. THE GOAL OF OUR PROPOSED RESEARCH ...

    SBIRPhase II1986Department of Health and Human Services
  10. RADIORHENIUM ANTIBODIES FOR RADIOIMMUNOTHERAPY

    Amount: $500,000.00

    THE OBJECTIVE OF THIS PHASE I SBIR PROJECT IS TO DEVELOP A RE-186 AGENT SUITABLE FOR LABELING BIFUNCTIONAL CHELATING AGENT ANTIBODY CONJUGATES. ALTHOUGH CHEMICALLY SIMILAR TO TC-99M, APPLICATION OF RE ...

    SBIRPhase II1986Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government